Back to Search Start Over

New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy

Authors :
Najwa El-Nachef
Robert C. Kersten
Grace E. Kim
Bryan J. Winn
Ivana Jankovic
Davin C. Ashraf
Source :
Ophthalmic Plastic & Reconstructive Surgery. 37:e160-e164
Publication Year :
2021
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2021.

Abstract

A patient with thyroid-associated ophthalmopathy was treated with teprotumumab and developed symptoms concerning for inflammatory bowel disease after her sixth infusion. Colonoscopy was performed, and mucosal biopsies identified evidence of active colitis consistent with a diagnosis of ulcerative colitis. Despite treatment with budesonide and mesalamine, the patient continued to be symptomatic one and a half months after cessation of teprotumumab and required infliximab to achieve good control of her inflammatory bowel disease. This case represents the first report of new-onset inflammatory bowel disease arising during treatment with teprotumumab.

Details

ISSN :
07409303
Volume :
37
Database :
OpenAIRE
Journal :
Ophthalmic Plastic & Reconstructive Surgery
Accession number :
edsair.doi...........7a80bc7fec5544c30de12dabd8f396eb
Full Text :
https://doi.org/10.1097/iop.0000000000001943